GlassScriptPhysician profile
Anna Whaley Burke
NPI 1306409768
$3,215.12
in general payments reported to CMS, 2019-2025
26 companies · $36.07 in 2025
The $36.07 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,916 · 2022: $539 · 2023: $682 · 2024: $40.92 · 2025: $36.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $709 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $709.40 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,044.49 | 2021-2024 | |
| Novo Nordisk INC | $547.01 | 2021-2023 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $261.51 | 2021 | |
| Amgen INC. | $208.12 | 2021-2022 | |
| Lilly USA, LLC | $172.36 | 2021-2023 | Mounjaro, Trulicity |
| Coopersurgical, INC. | $131.97 | 2021 | |
| Rhythm Pharmaceuticals, INC. | $107.70 | 2023 | Imcivree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.40 | 2021-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $98.47 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $77.99 | 2021-2023 | Nexletol, Contrave |
| Eisai INC. | $66.84 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $58.83 | 2022 | |
| Agile Therapeutics, INC. | $49.63 | 2021 | |
| Pfizer INC. | $46.49 | 2021-2023 | |
| Therapeuticsmd, INC. | $35.92 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $35.52 | 2021-2025 | |
| Arbor Pharmaceuticals, INC. | $28.05 | 2021 | |
| Endo Pharmaceuticals INC. | $20.70 | 2022 | |
| Exact Sciences Corporation | $19.02 | 2023 | Cologuard Collection Kit |
| Mylan Pharmaceuticals INC. | $16.09 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.99 | 2022 | |
| Allergan, INC. | $15.98 | 2022 | |
| Corcept Therapeutics | $14.40 | 2022 | |
| Astellas Pharma US INC | $13.80 | 2023 | Veozah |
| Avion Pharmaceuticals | $13.05 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Burke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.